Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

1.9K
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.9K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1.4K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.4K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

567
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
567
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

599
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
599
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

436
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
436

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variability in Cardiac Stress Test Interpretation: Agreement Between Enrollment Sites and Core Laboratories in the Global ISCHEMIA Trial.

Circulation. Population health and outcomes·2026
Same author

Questions Regarding the ISCHEMIA-PREDICT Mortality Risk Score.

European journal of preventive cardiology·2026
Same author

Residual Angina Following Complete Revascularization in the ISCHEMIA Trial: Frequency, Clinical Characteristics, Health Status, and Cardiovascular Outcomes.

Journal of the American Heart Association·2026
Same author

Sex Differences in Coronary Disease Health Status Outcomes: the ISCHEMIA Trial.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Multimodality Imaging to Determine Underlying Causes of Myocardial Infarction With Nonobstructive Coronary Arteries in Women and Men.

Circulation·2026
Same author

A point-based system to determine authorship eligibility in a large clinical trial: Insights from the ISCHEMIA trial's authorship nomination system.

Journal of clinical and translational science·2026

Related Experiment Video

Updated: Apr 11, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.8K

Mechanical circulatory support in cardiogenic shock.

Karl Werdan1, Stephan Gielen, Henning Ebelt

  • 1Department of Internal Medicine III, Heart Center, Martin-Luther-University Halle-Wittenberg, University Hospital Halle/Saale, Ernst-Grube-Str. 40, Halle/Saale 06120, Germany.

European Heart Journal
|September 10, 2013
PubMed
Summary

Mechanical circulatory support for cardiogenic shock complicating acute ST-elevation myocardial infarction (CSMI) is crucial but current devices, including IABP, ECMO, Impella, and TandemHeart, have not improved survival rates. Further research into optimal device timing and design is needed for better CSMI outcomes.

Keywords:
APACHE II scoreCardiogenic shockInterleukin 6 (IL-6)Left ventricular assist devicesMortality

More Related Videos

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

26.2K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.3K

Related Experiment Videos

Last Updated: Apr 11, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.8K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

26.2K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.3K

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Critical Care Medicine

Background:

  • Cardiogenic shock complicating acute ST-elevation myocardial infarction (CSMI) presents a significant clinical challenge with high mortality.
  • While mechanical circulatory support (MCS) is increasingly used, conservative management with catecholamines has limitations.
  • Percutaneous assist systems offer various circulatory support types, including intra-aortic balloon pumps (IABP), extracorporeal membrane oxygenation (ECMO), Impella, and TandemHeart.

Purpose of the Study:

  • To review the current landscape of mechanical circulatory support devices used in CSMI.
  • To evaluate the efficacy of commonly used percutaneous assist systems in improving outcomes for CSMI patients.
  • To identify gaps in current research and suggest future directions for improving CSMI management.

Main Methods:

  • Review of clinical studies and experience with hemodynamic improvement.
  • Analysis of data from the IABP-Shock II Trial regarding IABP use in CSMI.
  • Examination of randomized controlled trials (RCTs) comparing Impella and TandemHeart to IABP.

Main Results:

  • Decades of experience show hemodynamic improvements with MCS, but recent trials have yielded disappointing survival results.
  • The IABP-Shock II Trial found no significant reduction in 30-day mortality for CSMI patients treated with IABP.
  • Small RCTs indicated that Impella and TandemHeart did not reduce 30-day mortality compared to IABP.

Conclusions:

  • Current percutaneous mechanical circulatory support devices, as tested, have not demonstrated improved short- or long-term survival rates in CSMI.
  • There is a critical need for well-designed RCTs to investigate optimal timing and device design for MCS in CSMI.
  • Further research is essential to enhance patient outcomes in cardiogenic shock complicating myocardial infarction.